Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
J Liu, B Di, L Xu - Cytokine & Growth Factor Reviews, 2023 - Elsevier
Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has
multiple effective treatment options available and new therapeutic strategies are being …
multiple effective treatment options available and new therapeutic strategies are being …
Clinical advances in TNC delivery vectors and their conjugate agents
W Chen, Y Wu, J Wang, W Yu, X Shen, K Zhao… - Pharmacology & …, 2023 - Elsevier
Tenascin C (TNC), a glycoprotein that is abundant in the tumor extracellular matrix (ECM), is
strongly overexpressed in tumor tissues but virtually undetectable in most normal tissues …
strongly overexpressed in tumor tissues but virtually undetectable in most normal tissues …
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
L Li, J Lu, J Liu, J Wu, X Zhang, Y Meng, X Wu… - Frontiers in …, 2024 - frontiersin.org
Psoriasis is a chronic autoimmune inflammatory disease characterized by erroneous
metabolism of keratinocytes. The development of psoriasis is closely related to abnormal …
metabolism of keratinocytes. The development of psoriasis is closely related to abnormal …
Are all the IL-23 blockers the same in inflammatory bowel disease?
S Danese, L Peyrin-Biroulet - Nature Reviews Gastroenterology & …, 2024 - nature.com
A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic
treatment failure or loss of response over time. This article explores the effectiveness and …
treatment failure or loss of response over time. This article explores the effectiveness and …
Machine learning in antibody diagnostics for inflammatory bowel disease subtype classification
C Sokollik, A Pahud de Mortanges, AB Leichtle… - Diagnostics, 2023 - mdpi.com
Antibody testing in inflammatory bowel disease (IBD) can add to diagnostic accuracy of the
main subtypes Crohn's disease (CD) and ulcerative colitis (UC). Whether modern modeling …
main subtypes Crohn's disease (CD) and ulcerative colitis (UC). Whether modern modeling …
IL-22, a vital cytokine in autoimmune diseases
J Li, Z Wu, Y Wu, XY Hu, J Yang, D Zhu… - Clinical and …, 2024 - academic.oup.com
Summary Interleukin-22 (IL-22) is a vital cytokine that is dysregulated in various autoimmune
conditions including rheumatoid arthritis (RA), multiple sclerosis (MS), and Alzheimer's …
conditions including rheumatoid arthritis (RA), multiple sclerosis (MS), and Alzheimer's …
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
L Mateu-Arrom, L Puig - Expert Review of Clinical Pharmacology, 2024 - Taylor & Francis
Introduction Psoriasis is a chronic inflammatory skin disease often associated with several
comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes …
comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes …
Precision medicine in inflammatory bowel disease
Z Zeng, M Jiang, X Li, J Yuan… - Precision Clinical …, 2023 - academic.oup.com
Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-
relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC) …
relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC) …
Network pharmacology mechanisms and experimental verification of licorice in the treatment of ulcerative colitis
J Kong, Q Xiang, W Ge, Y Wang, F Xu, G Shi - Journal of …, 2024 - Elsevier
Ethnopharmacological relevance Licorice is widely used in the treatment of ulcerative colitis
(UC) and has good antioxidant and anti-inflammatory effects, but its specific active …
(UC) and has good antioxidant and anti-inflammatory effects, but its specific active …
Sequential immunotherapy: towards cures for autoimmunity
F Ramírez-Valle, JC Maranville, S Roy… - Nature Reviews Drug …, 2024 - nature.com
Despite major progress in the treatment of autoimmune diseases in the past two decades,
most therapies do not cure disease and can be associated with increased risk of infection …
most therapies do not cure disease and can be associated with increased risk of infection …